Advertisement
DHR vs LH
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Labcorp Holdings Inc. (LH) Stock Comparison
Key Takeaways
- Danaher Corporation (DHR) delivered a first-quarter adjusted earnings per share (EPS) beat at $2.06, surpassing estimates, though revenue came in at $5.95 billion.
- Labcorp Holdings Inc. (LH) shows year-to-date (YTD) gains of 5.27%, with its Q1 earnings report scheduled for April 30.
- LH trades at a lower price-to-earnings (P/E) ratio of 25.18 compared to DHR's 34.94, suggesting better value metrics currently.
- Market capitalization stands at approximately $128 billion for DHR versus $21.7 billion for LH, reflecting DHR's larger scale.
- Analysts rate LH as a Zacks Rank #2 (Buy) while DHR holds a #3 (Hold).
- Both stocks have faced short-term pressure in recent weeks amid broader healthcare sector volatility.
Introduction
Danaher Corporation (DHR) and Labcorp Holdings Inc. (LH) are prominent players in the diagnostics and life sciences sector, providing essential tools, services, and testing for healthcare innovation. This stock comparison evaluates their recent market performance, financial highlights, and positioning amid evolving industry dynamics such as biopharma demand and diagnostic advancements. Traders seeking exposure to healthcare stability and investors tracking relative value in medical diagnostics will find these insights valuable for assessing momentum, valuation, and growth potential in the current environment.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a global innovator in life sciences, diagnostics, and biotechnology tools, serving research, clinical, and industrial applications through segments like bioprocessing and diagnostics. Trading around $180 per share recently, the stock has shown resilience with YTD gains of approximately 21%. In recent market activity, DHR reported first-quarter results featuring adjusted EPS of $2.06, beating consensus estimates, supported by $5.95 billion in revenue and modest core growth. Sentiment has been influenced by strength in bioprocessing amid acquisition strategies, though broader biotech funding challenges have tempered gains in recent weeks. Price behavior reflects volatility, with shares rebounding post-earnings but remaining sensitive to sector headwinds.
LH Overview and Recent Performance
Labcorp Holdings Inc. (LH), a leading provider of laboratory diagnostic services, focuses on clinical testing, drug development, and companion diagnostics for pharmaceuticals. The stock trades near $263, posting YTD performance of 5.27% amid steady demand for testing volumes. Recent developments include FDA approvals for new tests and a rating upgrade to Buy, bolstering market positioning ahead of Q1 earnings on April 30. Performance has been relatively stable, with modest declines over the past month influenced by healthcare sector rotations. Investor sentiment remains positive on operational execution and growth in high-margin diagnostics, though upcoming results will shape near-term momentum.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI trading bots selected from a library of 351 total bots that trade thousands of tickers across diverse strategies. These curated agents employ advanced signal, virtual, and brokerage approaches, focusing on momentum, sector rotation, and trend analysis to outperform benchmarks—boasting annualized returns up to 227% and win rates of 70-80% for leading performers in recent periods. Only the most suitable bots for prevailing market conditions earn a spot, adapting to styles from day trading to long-term swings. Explore these high-performing tools to enhance your strategy across stocks like DHR and LH.
Head-to-Head Comparison
DHR and LH both anchor the diagnostics space, but DHR pursues a diversified model spanning life sciences instrumentation and bioprocessing, driving growth via innovation and acquisitions (M&A, mergers and acquisitions), while LH emphasizes laboratory services and volume-based testing. Recent momentum favors DHR with stronger YTD returns, contrasted by LH's value appeal through a lower P/E and Zacks Buy rating. Risk factors include regulatory shifts for both, though DHR faces biotech cyclicality and LH reimbursement pressures. Sector exposure tilts DHR toward high-growth R&D tools versus LH's stable clinical volumes, with market sentiment leaning toward LH for relative stability.
Tickeron AI Verdict
Tickeron’s AI analysis currently favors LH for its compelling value metrics, including a lower P/E ratio and stronger analyst ranking, alongside consistent diagnostics demand. While DHR demonstrates earnings momentum and scale advantages, LH's relative stability and upcoming catalysts position it probabilistically ahead in the near term amid healthcare rotations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a Hold and LH is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileLH’s FA Score has 1 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- LH’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 5 TA indicator(s) are bullish while LH’s TA Score has 4 bullish TA indicator(s).
- DHR’s TA Score: 5 bullish, 5 bearish.
- LH’s TA Score: 4 bullish, 5 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -1.61% price change this week, while LH (@Medical Specialties) price change was -4.00% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.70%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was -3.13%.
Reported Earning Dates
DHR is expected to report earnings on Jul 28, 2026.
LH is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (+0.70% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| DHR | LH | DHR / LH | |
| Capitalization | 126B | 20.9B | 603% |
| EBITDA | 7.08B | 2.06B | 343% |
| Gain YTD | -21.995 | 1.949 | -1,129% |
| P/E Ratio | 34.53 | 22.54 | 153% |
| Revenue | 24.8B | 14.1B | 176% |
| Total Cash | 5.7B | 981M | 581% |
| Total Debt | 18.5B | 7.24B | 255% |
DHR | LH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 75 | |
SMR RATING 1..100 | 80 | 68 | |
PRICE GROWTH RATING 1..100 | 60 | 56 | |
P/E GROWTH RATING 1..100 | 60 | 76 | |
SEASONALITY SCORE 1..100 | 30 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LH's Valuation (1) in the Servicestothe Health Industry industry is in the same range as DHR (10) in the Medical Specialties industry. This means that LH’s stock grew similarly to DHR’s over the last 12 months.
LH's Profit vs Risk Rating (75) in the Servicestothe Health Industry industry is in the same range as DHR (100) in the Medical Specialties industry. This means that LH’s stock grew similarly to DHR’s over the last 12 months.
LH's SMR Rating (68) in the Servicestothe Health Industry industry is in the same range as DHR (80) in the Medical Specialties industry. This means that LH’s stock grew similarly to DHR’s over the last 12 months.
LH's Price Growth Rating (56) in the Servicestothe Health Industry industry is in the same range as DHR (60) in the Medical Specialties industry. This means that LH’s stock grew similarly to DHR’s over the last 12 months.
DHR's P/E Growth Rating (60) in the Medical Specialties industry is in the same range as LH (76) in the Servicestothe Health Industry industry. This means that DHR’s stock grew similarly to LH’s over the last 12 months.
| DHR | LH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 56% | N/A |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 54% | 2 days ago 50% |
| Advances ODDS (%) | 8 days ago 54% | 19 days ago 56% |
| Declines ODDS (%) | 6 days ago 60% | 2 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 40% |
| Aroon ODDS (%) | 2 days ago 50% | 2 days ago 53% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +0.58% | ||
| TMO - DHR | 77% Closely correlated | -0.13% | ||
| A - DHR | 73% Closely correlated | -0.45% | ||
| RGEN - DHR | 68% Closely correlated | -4.05% | ||
| RVTY - DHR | 64% Loosely correlated | -0.96% | ||
| BIO - DHR | 64% Loosely correlated | -0.47% | ||
More | ||||
LH and
Correlation & Price change
A.I.dvisor indicates that over the last year, LH has been closely correlated with DGX. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if LH jumps, then DGX could also see price increases.